Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo‐controlled clinical trial
Epilepsia · 2023-10 · 64 (10) · 2653-2666
DOI: 10.1111/epi.17737 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Epilepsia, online erschienen am 17.08.2023. Verfasst von Joseph Sullivan und 18 weiteren Autor:innen. Beteiligte Einrichtung: University of California, San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Fenfluramine, Epilepsies, Myoclonic, Anticonvulsants. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Zogenix, Inc., now a part of UCB, Zogenix.
Abstract (Originalsprache)
Objective
This study was undertaken to assess the safety and efficacy of fenfluramine in the treatment of convulsive seizures in patients with Dravet syndrome.
Methods
This multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group, phase 3 clinical trial enrolled patients with Dravet syndrome, aged 2–18 years with poorly controlled convulsive seizures, provided they were not also receiving stiripentol. Eligible patients who had ≥6 convulsive seizures during the 6‐week baseline period were randomized to placebo, fenfluramine .2 mg/kg/day, or fenfluramine .7 mg/kg/day (1:1:1 ratio) administered orally (maximum dose = 26 mg/day). Doses were titrated over 2 weeks and maintained for an additional 12 weeks. The primary endpoint was a comparison of the monthly convulsive seizure frequency (MCSF) during baseline and during the combined titration–maintenance period in patients given fenfluramine .7 mg/kg/day versus patients given placebo.
Results
A total of 169 patients were screened, and 143 were randomized to treatment. Mean age was 9.3 ± 4.7 years (±SD), 51% were male, and median baseline MCSF in the three groups ranged 12.7–18.0 per 28 days. Patients treated with fenfluramine .7 mg/kg/day demonstrated a 64.8% (95% confidence interval = 51.8%–74.2%) greater reduction in MCSF compared with placebo ( p < .0001). Following fenfluramine .7 mg/kg/day, 72.9% of patients had a ≥50% reduction in MCSF compared with 6.3% in the placebo group ( p < .0001). The median longest seizure‐free interval was 30 days in the fenfluramine .7 mg/kg/day group compared with 10 days in the placebo group ( p < .0001). The most common adverse events (>15% in any group) were decreased appetite, somnolence, pyrexia, and decreased blood glucose. All occurred in higher frequency in fenfluramine groups than placebo. No evidence of valvular heart disease or pulmonary artery hypertension was detected. Significance The results of this third phase 3 clinical trial provide further evidence of the magnitude and durability of the antiseizure response of fenfluramine in children with Dravet syndrome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of California, San Francisco, San Francisco, California, USA.
- Department of Pediatric Neurology, University of Leuven, Leuven, Belgium.
- University College London, National Institute for Health and Care Research Biomedical Research Centre, Great Ormond Street Institute of Child Health, London, UK.
- New York University Langone Medical Center, New York, New York, USA.
- Meyer Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Florence, Italy.
- University of Colorado, Children's Hospital Colorado, Aurora, Colorado, USA.
ORCID-Profile: Lieven Lagae, J Helen Cross, Orrin Devinsky, Renzo Guerrini, Kelly G Knupp, Tilman Polster, Rima Nabbout, Bradley S Galer, Arnold R Gammaitoni, Michael Lock, Ingrid E Scheffer
Förderung
- Zogenix, Inc., now a part of UCB
- Zogenix
Zitieren
APA
Sullivan, J., Lagae, L., Cross, J. H., Devinsky, O., Guerrini, R., Knupp, K. G., Laux, L., Nikanorova, M., Polster, T., Talwar, D., Ceulemans, B., Nabbout, R., Farfel, G. M., Galer, B. S., Gammaitoni, A. R., Lock, M., Agarwal, A., Scheffer, I. E., & FAiRE DS Study Group (2023). Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo‐controlled clinical trial. Epilepsia, 64(10), 2653-2666. https://doi.org/10.1111/epi.17737
Vancouver
Sullivan J, Lagae L, Cross JH, Devinsky O, Guerrini R, Knupp KG, et al. Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo‐controlled clinical trial. Epilepsia. 2023;64(10):2653-2666. doi:10.1111/epi.17737
BibTeX
@article{Sullivan2023,
author = {Sullivan, Joseph and Lagae, Lieven and Cross, J Helen and Devinsky, Orrin and Guerrini, Renzo and Knupp, Kelly G and Laux, Linda and Nikanorova, Marina and Polster, Tilman and Talwar, Dinesh and Ceulemans, Berten and Nabbout, Rima and Farfel, Gail M and Galer, Bradley S and Gammaitoni, Arnold R and Lock, Michael and Agarwal, Anupam and Scheffer, Ingrid E and FAiRE DS Study Group, FAiRE DS Study Group},
title = {Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo‐controlled clinical trial},
journal = {Epilepsia},
year = {2023},
volume = {64},
number = {10},
pages = {2653--2666},
doi = {10.1111/epi.17737}
}
EUVIMED